Small molecule · developed by Harmony Biosciences Management
ZYN002 is a pharmaceutically manufactured cannabidiol formulated as a clear transdermal gel applied to the skin. It is studied in Fragile X Syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04977986 | Phase 3 | Fragile X Syndrome | Completed | HRMY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fragile X SyndromeFragile X Syndrome (FXS)
Updated Oct 18, 2026. Something wrong or missing? Report it on the HRMY page.
See HRMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HRMY catalysts and pipeline →